Please email us at for more information on any of these webinars
This 2-hour webinar webinar was presented by Harm Reduction Coalition’s William Matthews, Physician Assistant, on March 29th, 2017. The webinar focuses on Fentanyl, a potent, synthetic opioid pain medication that has been associated with the recent surge in opioid related overdose deaths. Fentanyl has been found as a contaminant in the illicit drug supply and plays a significant role in the current wave of overdose deaths in NYC and around the United States. The webinar explains how to recognize a fentanyl related overdose and how to use a harm reduction response.
This hour long webinar features Harm Reduction Coalition’s Hepatitis C Training and Policy Manager, Mike Selick, and Reed Vreerland, Direct of Policy at Housing Works was hosted by HepCure on March 21st, 2017. The webinar goes through the history, process, recommendations, and goals for the New York State Hepatitis C Elimination Summit which took place in Albany, NY on February 7th, 2017.
This 90-minute webinar aims to provide an overview of injecting drug user (IDU) cultural competency. The webinar opens by answering the questions “Why is there a need for IDU cultural competency?” and “What is IDU Cultural Competency?” while exploring facets of injecting drug user culture and experience. The webinar closes with a discussion of IDU cultural competency principles and practices, as well as a detailed question-and-answer segment.
A community-based developmental evaluation study was conducted that explores organizational development barriers for African-Americans to access leadership and decision making power within institutions and organizations providing HIV prevention services and programming using the harm reduction model.
Organized in observance of the inaugural African American Hepatitis C Action Day, this webinar on African American’s and Hepatitis C covered the following topics: Clinical issues in hepatitis C care and treatment for African Americans; the role of the Affordable Care Act in addressing prevention, treatment and access to care for people living with viral hepatitis; and recommendations for increasing testing, linkage and prevention efforts as well as access to treatment and care.